Interactions between the megakaryocyte/platelet-specific β1 tubulin and the secretory leukocyte protease inhibitor SLPI suggest a role for regulated proteolysis in platelet functions

Blood

Volumn 104, Issue 13, 2004, Pages 3949-3957

  Schulze, Harald ^b   Korpal, Manav ^b   Bergmeier, Wolfgang ^b   Italiano Jr , Joseph E ^b   Wahl, Sharon M ^b   Shivdasani, Ramesh A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; LEUKOCYTE ELASTASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUBULIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; INFLAMMATION; MEGAKARYOCYTE; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REDUCTION; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS;

EID: 10244244953     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-1179     Document Type: Article

References (56)

1. Radley JM, Scurfield G. The mechanism of platelet release. Blood. 1980;56:996-999.
2. Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood. 1995;85:402-413.
3. Radley JM, Haller CJ. The demarcation membrane system of the megakaryocyte: a misnomer? Blood. 1982;60:213-219.
4. Handagama PJ, Jain NC, Feldman BF, Farver TB, Kono CS. In vitro platelet release by rat megakaryocytes: effect of heterologous antiplatelet serum. Am J Vet Res. 1987;48:1147-1149.
5. Italiano JE Jr, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol. 1999;147:1299-1312.
6. White JG, Rao GH. Microtubule coils versus the surface membrane cytoskeleton in maintenance and restoration of platelet discoid shape. Am J Pathol. 1998;152:597-609.
7. Schwer HD, Lecine P, Tiwari S, Italiano JE Jr, Hartwig JH, Shivdasani RA. A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol. 2001;11:579-586.
8. Wang D, Villasante A, Lewis SA, Cowan NJ. The mammalian beta-tubulin repertoire: hematopoietic expression of a novel, heterologous beta-tubulin isotype. J Cell Biol. 1986;103:1903-1910.
9. Lecine P, Italiano JE Jr, Kim SW, Villeval JL, Shivdasani RA. Hematopoietic-specific beta 1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2. Blood. 2000;96:1366-1373.
10. Breitling F, Little M. Carboxy-terminal regions on the surface of tubulin and microtubules: epitope locations of YOL1/34, DM1A and DM1B. J Mol Biol. 1986;189:367-370.
11. Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature. 1998;391:199-203.
12. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct. 2001;30:397-420.
13. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A. 1986;83:6692-6696.
14. Eisenberg SP, Hale KK, Heimdal P, Thompson RC. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem. 1990;265:7976-7981.
15. Zitnik RJ, Zhang J, Kashem MA, et al. The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA. Biochem Biophys Res Commun. 1997;232:687-697.
16. Sallenave JM, Si-Ta har M, Cox G, Chignard M, Gauldie J. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol. 1997;61:695-702.
17. Zhu J, Nathan C, Ding A. Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor. Biochim Biophys Acta. 1999;1451:219-223.
18. Grutter MG, Fendrich G, Huber R, Bode W. The 2.5 A X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. EMBO J. 1988;7:345-351.
19. Ashcroft GS, Lei K, Jin W, et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med. 2000;6:1147-1153.
20. Nakamura A, Mori Y, Hagiwara K, et al. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med. 2003;197:669-674.
21. Walhout AJ, Vidal M. High-throughput yeast two-hybrid assays for large-scale protein interaction mapping. Methods. 2001;24:297-306.
22. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 1995;81:695-704.
23. Tiwari S, Italiano JE Jr, Barral DC, et al. A role for Rab27b in NF-E2-dependent pathways of platelet formation. Blood. 2003;102:3970-3979.
24. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000;97:13835-13840.
25. Furman C, Short SM, Subramanian RR, Zetter BR, Roberts TM. DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism. J Biol Chem. 2002;277:7962-7969.
26. Italiano JE Jr, Bergmeier W, Tiwari S, et al. Mechanisms and implications of platelet discoid shape. Blood. 2003;101:4789-4796.
27. Bhattacharyya A, Watson FL, Pomeroy SL, Zhang YZ, Stiles CD, Segal RA. High-resolution imaging demonstrates dynein-based vesicular transport of activated Trk receptors. J Neurobiol. 2002;51:302-312.
28. Nakajima K, Powers JC, Ashe BM, Zimmerman M. Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase: studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem. 1979;254:4027-4032.
29. Marchesi VT, Ngo N. In vitro assembly of multiprotein complexes containing alpha, beta, and gamma tubulin, heat shock protein HSP70, and elongation factor 1 alpha. Proc Natl Acad Sci U S A. 1993;90:3028-3032.
30. Nakazawa M, Moreira D, Laurent J, Le Guyader H, Fukami Y, Ho K. Biochemical analysis of the interaction between elongation factor 1alpha and alpha/beta-tubulins from a ciliate, Tetrahymena pyriformis. FEBS Lett. 1999;453:29-34.
31. Moore RC, Cyr RJ. Association between elongation factor-1alpha and microtubules in vivo is domain dependent and conditional. Cell Motil Cytoskeleton. 2000;45:279-292.
32. Tablin F, Castro M, Leven RM. Blood platelet formation in vitro: the role of the cytoskeleton in megakaryocyte fragmentation. J Celi Sci. 1990;97:59-70.
33. Seemuller U, Arnhold M, Fritz H, et al. The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease): complete amino acid sequence as revealed by protein and cDNA sequencing and structural homology to whey proteins and Red Sea turtle proteinase inhibitor. FEBS Lett. 1986;199:43-48.
34. Song X, Zeng L, Jin W, et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med. 1999;190:535-542.
35. Sumi Y, Muramatsu H, Hata K, Ueda M, Muramatsu T. Secretory leukocyte protease inhibitor is a novel inhibitor of fibroblast-mediated collagen gel contraction. Exp Cell Res. 2000;256:203-212.
36. Sallenave JM. The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res. 2000;1:87-92.
37. White JG, Estensen RD. Influence of cytochalasin B (CB) on platelet aggregation. J Lab Clin Med. 1971;78:849-850.
38. Fuste B, Diaz-Ricart M, Jensen MK, Ordinas A, Escolar G, White JG. TRAP induces more intense tyrosine phosphorylation than thrombin with differential ultrastructural features. Am J Pathol. 2002;160:2245-2252.
39. Wright CD, Kennedy JA, Zitnik RJ, Kashem MA. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor. Biochem Biophys Res Commun. 1999;254:614-617.
40. Lewis SA, Gu W, Cowan NJ. Free intermingling of mammalian beta-tubulin isotypes among functionally distinct microtubules. Cell. 1987;49:539-548.
41. Luduena RF. Are tubulin isotypes functionally significant? Mol Biol Cell. 1993;4:445-457.
42. Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997;88:417-426.
43. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103:2096-2104.
44. Garcia A, Prabhakar S, Hughan S, et al. Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood. 2004;103:2088-2095.
45. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood. 1998;92:3035-3041.
46. Zhang D, Simmen RC, Michel FJ, Zhao G, ValeCruz D, Simmen FA. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem. 2002;277:29999-30009.
47. Tseng CC, Tseng CP. Identification of a novel secretory leukocyte protease inhibitor-binding protein involved in membrane phospholipid movement. FEBS Lett. 2000;475:232-236.
48. Zhu J, Nathan C, Jin W, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell. 2002;111:867-878.
49. Mellet P, Ermolieff J, Bieth JG. Mapping the heparin-binding site of mucus proteinase inhibitor. Biochemistry. 1995;34:2645-2652.
50. Ying QL, Kemme M, Simon SR. Functions of the N-terminal domain of secretory leukoprotease inhibitor. Biochemistry. 1994;33:5445-5450.
51. De Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood. 2002;100:1310-1317.
52. Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD. The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol. 2000;67:471-478.
53. Bank U, Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. J Leukoc Biol. 2001;69:197-206.
54. Renesto P, Balloy V, Chignard M. Inhibition by human leukocyte elastase of neutrophil-mediated platelet activation. Eur J Pharmacol. 1993;248:151-155.
55. Allen DH, Tracy PB. Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface. J Biol Chem. 1995;270:1408-1415.
56. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 1996;383:441-443.